Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 309, Issue -, Pages 47-50Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2017.05.006
Keywords
Natalizumab; Multiple sclerosis; Lymphocytes; CD4; CD8
Categories
Ask authors/readers for more resources
Although improved, the risk of progressive multifocal leukoencephalopathy is a constant threat for patient affected by multiple sclerosis treated with natalizumab. We performed a 24 months longitudinal study aimed to evaluate the total WBC and lymphocytes subsets modifications and their correlations with anti-JCV antibody index after 1 and 2 years of natalizumab treatment. Natalizumab induced an increase of WBC, total and C19 + lymphocytes together with a decrease of CD3 +, CD4 + T lymphocytes and CD4/CD8 ratio, which was positively related to anti-JCV antibodies index at month 0, 12 and 24. Our study confirms that lymphocytes subsets are modified under NAT therapy. Implications of lymphocyte subsets alterations in the pathogenesis of PML are under analyses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available